A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

Archives of General Psychiatry

Volumn 56, Issue 1, 1999, Pages 21-27

  Goff, Donald C ^a   Tsai, Guochuan ^b   Levitt, James ^b   Amico, Edward ^b   Manoach, Dara ^b   Schoenfeld, David A ^b   Hayden, Doug L ^b   McCarley, Robert ^b   Coyle, Joseph T ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYCLOSERINE; GLYCINE; HOMOVANILLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; AMINO ACIDS; ANTIPSYCHOTIC AGENTS; CYCLOSERINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032902238     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.1.21     Document Type: Article

References (49)

1. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998-1007.
2. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry. 1996;3:241-253.
3. Javitt D, Zukin S. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308.
4. Krystal JH, Karper LP, Seibyl JP. Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
5. Lawlor BA, Davis KL. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry. 1992;31: 337-350.
6. Olney JW. New mechanisms of excitatory transmitter neurotoxicity. J Neural Transm Suppl. 1994;43:47-51.
7. Huettner JE. Competitive antagonism of glycine at the N-methyl-D-aspartate (NMDA) receptor. Biochem Pharmacol. 1991;41:9-16.
8. Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 1988;241:835-837.
9. Waziri R. Glycine therapy of schizophrenia [letter]. Biol Psychiatry. 1988;23: 209-214.
10. Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol. 1989;12: 416-424.
11. Costa J, Khaled E, Sramek J, Bunney W, Potkin SG. An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics [letter]. J Clin Psychopharmacol. 1990;10:71-72.
12. Javitt DC, Zylberman I, Zukin SR, Heresco LU, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 1994;151: 1234-1236.
13. Heresco-Levy U, Javitt D, Ermilov M, Mordel C. Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 1996;169:610-617.
14. Henderson G, Johnson JW, Ascher P. Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-D-aspartate receptor. J Physiol. 1990;430:189-212.
15. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 1990;510:158-160.
16. Hanngren H, Hansson E, Ullberg S. An autoradiographic study of the distribution of tritium-labeled cycloserine in mice. Antibiot Chemother. 1961;12:46-54.
17. Nair KGS, Epstein IG, Baron H, Mulinos MG. Absorption, distribution, and excretion of cycloserine in man. Antibiot Ann. 1956:136-140.
18. Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995; 152:1213-1215.
19. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-Cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996;153:1628-1630.
20. Van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 1996;40:1298-1300.
21. Rosse R, Fay-McCarthy M, Kendrick K, Davis R, Deutsch S. D-Cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol. 1996;19:444-450.
22. Kirkpatrick B, Buchanan R, McKenney P. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119-123.
23. Simpson GM, Angus JWS. Drug-induced extrapyramidal disorders. Acta Psychiatr Scand Suppl. 1970;212:11-19.
24. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1981.
25. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
26. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Dept of Health, Education, and Welfare; 1976.
27. Sternberg S. High-speed scanning in human memory. Science. 1966;153:652-654.
28. Miller G, Selfridge J. Verbal context and the recall of meaningful material. Am J Psychol. 1950;63:176-185.
29. Manschreck TC, Maher BA, Rosenthal JE, Berner J. Reduced primacy and related features in schizophrenia. Schizophr Res. 1991;5:35-41.
30. Maher B, Manschreck T, Woods B, Yurgelun-Todd D, Tsuang M. Frontal brain volume and context effects in short-term recall in schizophrenia. Biol Psychiatry. 1995;37:144-150.
31. Jones LR. Colorimetric determination of cycloserine, a new antibiotic. Anal Chem. 1956;28:39-41.
32. Jones BN. Amino acids by ophthaldialdehyde precolumn derivatization and reverse-phase HPLC. In: Shively JE, ed. Method of Protein Microcharacterization. Clifton, NJ: Humana Press; 1986:121-151.
33. Laird N, Ware J. Random-effects models for longitudinal data. Biometrics. 1982; 38:963-974.
34. Little R, Rubin D. Statistical Analysis With Missing Data. New York, NY: Wiley & Sons Inc. 1987.
35. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates: 1988.
36. Marder S, Davis J, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American Trials. J Clin Psychiatry. 1997;58:538-546.
37. Simeon J, Fink M, Itil T, Ponce D. D-Cycloserine therapy of psychosis by symptom provocation. Comp Psychiatry. 1970;11:80-88.
38. Patel J, Zinkand WC, Thompson C, Keith R. Salama A. Role of glycine in the N-methyl-D-aspartate-mediated neurotoxicity. J Neurochem. 1990;54:849-854.
39. Yamamoto BK, Cooperman MA. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci. 1994;14:4159-4166.
40. Goff DC, Tsai G, Beal MF, Coyle JT. Tardive dyskinesia and substrates of energy metabolism in CSF. Am J Psychiatry. 1995;152:1730-1736.
41. Carpenter WT Jr, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145:578-583.
42. Breier A, Buchanan R, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994;151:20-26.
43. Carpenter WT, Conley RR. Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry. 1995;152:827-832.
44. Meltzer HY. Clozapine: is another view valid? Am J Psychiatry. 1995;152: 821-825.
45. Fletcher EJ, MacDonald JF. Haloperidol interacts with the strychnine-insensitive glycien site at the NMDA receptor in cultured mouse hippocampal neurones. Eur J Pharmacol. 1993;235:291-295.
46. Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. Neuroreport. 1995; 6:2500-2504.
47. McCoy L, Richfield EK. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci Lett. 1996;213:137-141.
48. Supplisson S, Bergman C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci. 1997;17:4580-4590.
49. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994:257:7-12.